Bristol-Myers Squibb (NYSE:BMY) Shares Sold by Telos Capital Management Inc.

Telos Capital Management Inc. decreased its position in shares of Bristol-Myers Squibb (NYSE:BMY - Free Report) by 26.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 192,259 shares of the biopharmaceutical company's stock after selling 68,245 shares during the quarter. Bristol-Myers Squibb accounts for approximately 1.2% of Telos Capital Management Inc.'s investment portfolio, making the stock its 27th largest position. Telos Capital Management Inc.'s holdings in Bristol-Myers Squibb were worth $9,865,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the company. Dakota Wealth Management bought a new stake in shares of Bristol-Myers Squibb during the 1st quarter valued at approximately $332,000. Covestor Ltd increased its holdings in shares of Bristol-Myers Squibb by 111.5% during the first quarter. Covestor Ltd now owns 2,052 shares of the biopharmaceutical company's stock worth $150,000 after buying an additional 1,082 shares in the last quarter. NewEdge Advisors LLC lifted its stake in shares of Bristol-Myers Squibb by 53.2% in the 1st quarter. NewEdge Advisors LLC now owns 165,336 shares of the biopharmaceutical company's stock valued at $12,075,000 after acquiring an additional 57,444 shares during the last quarter. Ergoteles LLC bought a new stake in Bristol-Myers Squibb during the 1st quarter worth $1,997,000. Finally, Mackenzie Financial Corp grew its holdings in shares of Bristol-Myers Squibb by 25.1% during the first quarter. Mackenzie Financial Corp now owns 338,563 shares of the biopharmaceutical company's stock worth $24,725,000 after purchasing an additional 68,018 shares during the last quarter. 76.41% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

BMY has been the topic of a number of research reports. Societe Generale lowered shares of Bristol-Myers Squibb from a "buy" rating to a "hold" rating in a report on Monday, March 11th. William Blair restated a "market perform" rating on shares of Bristol-Myers Squibb in a research report on Monday, April 1st. Wells Fargo & Company decreased their target price on shares of Bristol-Myers Squibb from $58.00 to $51.00 and set an "equal weight" rating for the company in a research report on Tuesday, February 6th. StockNews.com cut shares of Bristol-Myers Squibb from a "strong-buy" rating to a "buy" rating in a research report on Monday. Finally, Redburn Atlantic lowered shares of Bristol-Myers Squibb from a "buy" rating to a "neutral" rating and dropped their target price for the company from $77.00 to $54.00 in a report on Tuesday, February 6th. One investment analyst has rated the stock with a sell rating, fifteen have issued a hold rating and four have issued a buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Hold" and a consensus price target of $61.12.

Bristol-Myers Squibb Stock Down 0.9 %

Shares of Bristol-Myers Squibb stock traded down $0.43 on Wednesday, hitting $47.83. The company had a trading volume of 11,759,869 shares, compared to its average volume of 15,847,523. The stock has a market capitalization of $96.94 billion, a price-to-earnings ratio of 12.50, a P/E/G ratio of 1.46 and a beta of 0.39. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.31 and a current ratio of 1.43. Bristol-Myers Squibb has a 1 year low of $47.58 and a 1 year high of $70.93. The stock has a 50 day moving average of $51.27 and a 200-day moving average of $51.62.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last posted its earnings results on Friday, February 2nd. The biopharmaceutical company reported $1.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.55 by $0.15. The firm had revenue of $11.48 billion during the quarter, compared to analyst estimates of $11.19 billion. Bristol-Myers Squibb had a net margin of 17.83% and a return on equity of 50.95%. The business's revenue was up .6% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.82 EPS. As a group, sell-side analysts forecast that Bristol-Myers Squibb will post 6.63 earnings per share for the current year.

Bristol-Myers Squibb Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, May 1st. Investors of record on Friday, April 5th will be issued a $0.60 dividend. The ex-dividend date of this dividend is Thursday, April 4th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 5.02%. Bristol-Myers Squibb's dividend payout ratio (DPR) is presently 62.18%.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.